ReviewThe Journal of dermatology2021
Rhododendrol-induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments in comparison with vitiligo.
Review in The Journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025).The Journal of dermatology · 2026Guideline
- Staurosporine Drives Non-Canonical Melanocyte Maturation by Coupling β-Catenin Signaling to Actin-Dependent Dendrite Remodeling.Pigment cell & melanoma research · 2026Article
- Aberrant laminin signaling drives melanocyte dedifferentiation and unveils a tractable therapeutic target in vitiligo.Nature communications · 2026Article
- Melanin Metabolism: A Novel Oxidative Degradation Mechanism and Regulation by Hydrolyzed Conchiolin Protein.Journal of cosmetic dermatology · 2026Article
- In Vitro Safety Profiling and Leukoderma-Relevant Hazard Assessment of Raspberry Ketone VersusMolecules (Basel, Switzerland) · 2026Article
- Pathogenesis of Chemical Leukoderma and Chemical-Induced Vitiligo.The Journal of dermatology · 2026Review
- Pathogenesis of Vitiligo: Integrating Immune and Non-Immune Cell Crosstalk.The Journal of dermatology · 2026Review
- A Cell-Based Evaluation of the Tyrosinase-Mediated Metabolic Activation of Leukoderma-Inducing Phenols, II: The Depletion ofBiomolecules · 2025Article
- Treatment with Ascorbyl Glucoside-Arginine Complex Ameliorates Solar Lentigos.International journal of molecular sciences · 2024Article
- Chemical- and Drug-Induced Allergic, Inflammatory, and Autoimmune Diseases Via Haptenation.Biology · 2023Review
- Morphological Alterations and Increased S100B Expression in Epidermal Langerhans Cells Detected in Skin from Patients with Progressive Vitiligo.Life (Basel, Switzerland) · 2021Article
- Update on the pathogenesis of vitiligo.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
A small proportion of individuals utilizing cosmetics containing rhododendrol developed leukoderma with various pathological conditions, in some cases indistinguishable from vitiligo. In this review, we investigate and evaluate the major considerations for developing rhododendrol-induced leukoderma based on data from original or review articles published in the literature to provide a wide range of information regarding the pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments. We compile and discuss the latest information, including data related to the cytotoxicity of rhododendrol, cytoprotective functions, and involvement of the immune system, and consider the possibility of novel treatments based on the differences between individual patients and on the mechanism underlying the onset of the condition. Understanding the pathophysiology of rhododendrol-induced leukoderma helps not only elucidate the mechanisms of non-segmental vitiligo onset and progression, but also suggests prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.